Quality and Biocompatibility Support for Indian Medical Device Manufacturers
Prepare a clearer device, quality and biological-evaluation evidence file for domestic or export review. Identify gaps, prioritise the next documentation steps, and connect the work to your intended market.
India medical device consulting strengths
Target-Market Framing
Connect your India-based team's biological-safety evidence with the documentation questions for its intended market.
ISO 10993 Readiness
BEP, BER, TRA, endpoint, contact, material, and test-planning logic before lab work creates rework.
Quality and Risk Lens
Practical checks that connect biological evaluation with ISO 14971 risk files and ISO 13485 readiness signals.
Domestic + Export Planning
Choose India/CDSCO, FDA 510(k), or EU MDR documentation support according to where your device will be marketed.
For Indian MedTech teams that need a stronger file before scale-up, testing, or export conversations
Use this route when your team is based in India and needs to connect device, quality, risk and biological-evaluation documents for a defined domestic or export project.
Startup to Regulatory File
You have a prototype, material choices, and early testing plans, but the device file is not yet structured for CDSCO, investor, FDA, or EU-style questions.
Manufacturing Scale-Up
You are moving toward production, supplier control, sterilization, packaging, or validation work and want the file logic to keep up.
Export-Oriented Planning
India is one market, but the same evidence may later need to support FDA, EU MDR, UK, Middle East, distributor, or customer review.
Testing Before Strategy
A lab quote exists, but the device contact profile, endpoint rationale, sample state, or chemistry/TRA logic has not been documented clearly.
A practical readiness review for Indian MedTech teams
The goal is to identify the file gaps that can slow CDSCO, customer, FDA, EU MDR, or investor review before expensive testing or submission work begins.
Device and Pathway Map
Intended use, contact classification, device state, likely regulatory pathway questions, and the documents that need to line up first.
Quality Readiness Check
A focused check of design-control, supplier, sterilization, packaging, change-control, and document-control signals that affect the technical file.
Risk-File Alignment
Review of whether biological hazards, material risks, process residues, and residual-risk language connect properly to ISO 14971 logic.
Biological Evaluation Strategy
Biological Evaluation Plan (BEP), Biological Evaluation Report (BER), endpoint, waiver, literature, chemistry, and Toxicological Risk Assessment (TRA) strategy tied to ISO 10993 and the device's real clinical use.
Testing Plan Before Lab Spend
Review of whether proposed cytotoxicity, sensitization, irritation, systemic toxicity, chemistry, or sterilization evidence matches the file need.
Cross-Market Reuse Plan
Clear notes on what can be reused across CDSCO, FDA, EU MDR, and customer review, and what should be reframed for each market.
Support for your manufacturing team and intended market
This support is for manufacturers based in India, whether the device is intended for the domestic market or export. Choose domestic or export-market documentation support according to where the device will be marketed.
Evidence aligned with your intended market
The review connects biological evaluation, quality evidence, and risk logic to your stated domestic or export markets. Reuse is assessed rather than assumed.
Clear next-step recommendations
The output focuses on readiness, documentation, biocompatibility, risk, and export alignment, with separate next steps identified when formal local filing support is needed.
Independent advisory support
MedDev Advisory is independent. It is not affiliated with, endorsed by, or approved by CDSCO, the Government of India, testing labs, or medical-device parks.
Plan the evidence alongside manufacturing growth
As your team develops or scales a device in India, keep the quality, risk and biological-evaluation file aligned with your intended domestic or export market.
Manufacturing capacity is expanding
PIB updates describe medical-device parks in Uttar Pradesh, Madhya Pradesh, and Tamil Nadu, with shared infrastructure that can include sterilization, biocompatibility testing, toxicology, component testing, and validation support. Read PIB manufacturing update.
Import substitution and export ambition create quality pressure
A 2026 PIB update notes that imports make up a large share of domestic medical-device consumption and confirms three medical-device parks are being established. That makes quality, testing strategy, and file readiness commercially important. Read PIB medical device park update.
CDSCO remains the official India reference point
For India-specific notices, forms, and device-related regulatory information, teams should verify the current official CDSCO Medical Devices and Diagnostics portal rather than relying on old summaries. Open CDSCO medical devices portal.
Innovation support does not replace a defensible file
Initiatives such as MedTech Mitra can help innovators understand parts of the ecosystem, but technical, quality, risk, and biological-evaluation documentation still need disciplined project-specific work. Open MedTech Mitra.
Start with evidence triage, then choose the right scope
Start with a free initial fit check. Any document review or paid work is scoped and agreed separately before it begins.
Share Device Inputs
Share a non-confidential summary of the device, intended use, target markets, current evidence, and the decision you need to make. Detailed documents can follow through an agreed channel.
Map File Risk
An agreed document review identifies whether the main gap is quality readiness, risk-management alignment, ISO 10993 strategy, testing scope, or cross-market documentation reuse.
Prioritize Evidence
Decide what should be corrected first: contact classification, material story, BEP, BER, TRA, chemistry, supplier evidence, sterilization, or submission summary.
Define the Scope
Agree a proposal for any follow-on gap review, BEP/BER/TRA support, CDSCO documentation planning, FDA/EU alignment, or document remediation.
Questions Indian device teams should ask before a scope begins
Is this only for devices marketed in India?
No. This page is for manufacturers based in India preparing for domestic or export review. The intended market, not the manufacturer's location, determines which market-specific documentation questions need attention.
How is this different from CDSCO strategy support?
The CDSCO page addresses an India-market biological-evaluation or documentation question. This page starts with your manufacturing team's broader device, quality, risk and evidence-readiness needs, then connects them to the intended market.
Does this include licensing, filing, lab testing, or QMS certification?
No. This is advisory evidence review and documentation support, not licensing, filing, local-agent representation, laboratory testing, or quality management system (QMS) certification. Manufacturer and applicant responsibilities remain with the responsible organisation.
What should I send first?
Begin with a non-confidential device summary, intended use, target markets, available evidence, and the decision you need to make. If work proceeds, agree how to share materials, contact category, sterilization state, testing plans, drawings, packaging information, and existing quality/risk or BEP/BER/TRA files.
Build a clearer evidence file for your intended market.
Tell us about your device, manufacturing stage, intended domestic or export markets, and the evidence question you need to resolve. Start with a free fit check; paid review or documentation work is agreed separately.